Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-Year treatment retention, outcomes and status

Addiction

Volumn 102, Issue 9, 2007, Pages 1432-1442

  Anglin, M Douglas ^a   Conner, Bradley T ^a   Annon, Jeffery ^a   Longshore, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Drug abuse treatment outcomes; LAAM maintenance; Methadone maintenance; Narcotic replacement therapy; Opiate addiction; Retention

Indexed keywords

LEVACETYLMETHADOL; METHADONE; OPIATE;

ABSTINENCE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; EXPERIMENTAL STUDY; FEMALE; FOLLOW UP; HEALTH STATUS; HELP SEEKING BEHAVIOR; HOSPITAL MANAGEMENT; HUMAN; INTERVIEW; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; SAMPLING; SELF REPORT; TREATMENT OUTCOME; UNITED STATES; URINALYSIS;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; LOS ANGELES; MALE; METHADONE; METHADYL ACETATE; MIDDLE AGED; NARCOTICS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 34547829548     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2007.01935.x     Document Type: Article

References (44)

1. U.S. Food and Drug Administration (FDA) Talk Paper T93-36. FDA Announces LAAM Approved to Treat Drug Dependence. (August 3, 1993). Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS00517.html (accessed 15 March 2006).
2. U.S. Food and Drug Administration (FDA) Talk Paper T02-38. FDA Announces Subutex and Suboxone Approved to Treat Opiate Dependence (October 8, 2002). Available at: http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01165.html (accessed 15 March 2006).
3. Clark N., Lintzeris N., Gijsbers A., Whelan G., Dunlop A., Ritter A. et al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD002210. DOI: 10.1002/14651858.CD002210.
4. Freedman R. R., Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed opiate addicts. Drug Alcohol Depend 1981 8 : 215 22.
5. Jaffe J. H., Schuster C. R., Smith B. B., Blachley P. H. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users. JAMA 1970 211 : 1834 6.
6. Jaffe J. H., Senay E. C., Schuster C. R., Renault P. R. Methadyl acetate versus methadone: a double-blind study in opiate users. JAMA 1972 222 : 437 42.
7. Johnson R. E., Chutuape M. A., Strain E. C., Walsh S. L., Stitzer M. L., Bigelow G. E. A comparison of LAAM, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000 343 : 1290 7.
8. Ling W., Charuvastra V. C., Kaim S. C., Klett C. J. Methadyl acetate and methadone as maintenance treatments for opiate addicts. Arch Gen Psychiatry 1976 33 : 709 20.
9. Ling W., Klett J., Gillis R. D. A cooperative clinical study of methadyl acetate 1. Three-times-a-week regimen. Arch Gen Psychiatry 1978 35 : 345 53.
10. Marsch L. A., Stephens M. A. C., Mudric T., Strain E. C., Bigelow G. E., Johnson R. E. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol 2005 13 : 293 302.
11. Senay E. C., Dorus W., Renault P. F. Methadyl acetate and methadone: an open comparison. JAMA 1977 237 : 138 42.
12. Trueblood B., Judson B. A., Goldstein A. Acceptability of methadyl acetate (LAAM) as compared with methadone in a treatment program for opiate addicts. Drug Alcohol Depend 1978 3 : 125 32.
13. White J. M., Danz C., Kneebone J., La Vincente S. F., Newcombe D. A. L., Ali R. L. Relationship between LAAM-methadone preference and treatment outcomes. Drug Alcohol Depend 2002 66 : 295 301.
14. Sorenson J. L., Hargreaves W. A., Weinberg J. A. Withdrawal from heroin in three or six weeks-comparison of methadyl acetate and methadone. Arch Gen Psychiatry 1982 39 : 167 71.
15. Longshore D., Annon J., Anglin M. D., Rawson R. A. Levo-alpha- acetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction 2005 100 : 1131 9.
16. Newcombe D. A. L., Bochner F., White J. M., Somogyi A. A. Evaluation of levo-alpha-acetylmethadol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug Alcohol Depend 2004 76 : 63 72.
17. Eissenberg T., Bigelow G. E., Strain E. C., Walsh S. L., Brooner R. K., Stitzer M. L. et al. Dose-related efficacy of levo-methadyl-acetate for treatment of opioid dependence. A randomized clinical trial. JAMA 1997 277 : 1945 51.
18. Tennant F. S., Rawson R. A., Pumphrey E., Seecof R. Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). JAMA 1986 3 : 195 202.
19. Kleber H. D. Pharmacologic Treatments for Heroin and Cocaine Dependence. Am J Addict 2003 12 : S5 18.
20. Marinelli-Casey P., Domier C. P., Rawson R. A. The gap between research and practice in substance abuse treatment. Psychiatr Serv 2002 53 : 984 7.
21. Rawson R. A., Hasson A. L., Huber A. M., McCann M. J., Ling W. A 3-year progress report on the implementation of LAAM in the United States. Addiction 1998 93 : 533 40.
22. Deamer R. L., Wilson D. R., Clark D. S., Prichard J. G. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001 20 : 7 14.
23. Peles E., Bodner G., Kreek M. J., Rados V., Adelson. M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients-a cross-sectional study. Addiction 2006 102 : 289 300.
24. The European Agency for the Evaluation of Medicinal Products. EMEA Public Statement of the Recommendation to Suspend the Marketing Authorization Fro ORLAAM (Levacetylmethadol) in the. European Union. Available at: http://www.emea.europa.eu/pdfs/human/press/pus/877601en.pdf (accessed 5 April 2007).
25. Krantz M. J., Lewkowiez L., Hays H., Woddroffe M. A., Robertson A. D., Mehler P. S. Torsade de Pointes associated with very-high-dose methadone. Ann Internal Med 2002 137 : 501 4.
26. U.S. Food and Drug Administration (FDA) Talk Paper T01-15. FDA Announces Labeling Changes Following Cardiac Adverse Events with Addiction Drug (April 20, 2001).Available at: http://www.fda.gov/bbs/topics/answers/2001/ans01076.html (accessed 15 March 2006).
27. Huber A., Ling W., Fradis J., Charuvastra V. C. Comparison of the effects of methadone and LAAM on the electrocardiogram. Drug Alcohol Depend 2001 63 : S70.
28. U.S. Food and Drug Administration Product Discontinuation Notice NDC 0054-3649-63 (August 23, 2003). Available at: http://www.fda.gov/cder/drug/ shortages/orlaam.htm (accessed 15 March 2006).
29. Ling W., Rawson R. A., Anglin M. D. Agonist pharmacotherapies for opiate dependence: comparing the development and implementation of methadone and LAAM. In : Sorensen J. L., Rawson R., Guydish J., Zweben J., editors. Drug Abuse Treatment Through Collaboration. Washington, DC : American Psychological Association 2002, p. 107 19.
30. Amato L., Davoli M., Perucci C. A., Ferri M., Faggiano F., Mattick R. P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005 28 : 321 9.
31. Farré M., Mas A., Torrens A., Moreno V., Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002 65 : 283 90.
32. Ritter A., Lintzeris N., Clark N., Jozica J., Kutin J. J., Bammer G. et al. A randomized trial comparing levo-alpha-acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction 2003 98 : 1605 13.
33. Glanz M., Klawansky S., McAullife W., Chalmers T. Methadone versus 1-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. Am J Addict 1997 4 : 339 49.
34. Oliveto A. H., Farren C., Kosten T. R. Effects of LAAM dose on opiate use in opioid-dependent patients: a pilot study. Am J Addict 1998 7 : 272 82.
35. SPSS for Windows, Release 13.0.1. Chicago : SPSS Inc 2004.
36. Gibbons R. D., Hedeker D., Elkin I., Waternaux C., Kraemer H. C., Greenhouse J. B. et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH treatment of depression collaborative research program dataset. Arch Gen Psychiatry 1993 50 : 739 50.
37. Hedeker D., Gibbons R. D. A random-effects ordinal regression model for multilevel analysis. Biometrics 1994 50 : 933 44.
38. Hedeker D., Gibbons R. D. Longitudinal Data Analysis. New York : Wiley 2006.
39. Verbeke G., Molenberghs G. Linear Mixed Models for Longitudinal Data. New York : Springer 2000.
40. Hedeker D., Mermelstein R. J. Analysis of longitudinal substance use outcomes using ordinal random-effects regression models. Addiction 2000 95 : S381 94.
41. Stiratelli R., Laird N. M., Ware J. H. Random-effects models for serial observations with binary response. Biometrics 1984 40 : 961 71.
42. Hedeker D., Gibbons R. D. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997 2 : 64 78.
43. R Development Core Team. The Comprehensive R Archive Network. Available at: http://cran.r-project.org/ (accessed 13 April 2006).
44. National Institutes of Health (NIH). NIH Consensus Statement, 17-19 November. Effective Medical Treatment of Opiate Addiction. Bethesda, MD : NIH 1997.